Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization

From TSOC ACS-DM registry

Cheng-An Wang, MD\textsuperscript{a,b,c}, Yi-Chen Hsieh, PhD\textsuperscript{d,e,f}, Chun-Yao Huang, MD, PhD\textsuperscript{b,c,g}, Ju-Chi Liu, MD, PhD\textsuperscript{b,c,h}, Ming-Hsiung Hsieh, MD\textsuperscript{a,b,c}, Yung-Kuo Lin, MD, PhD\textsuperscript{a,b,c}, Jong-Shiuan Yeh, MD\textsuperscript{a,b,c,*}

Abstract

Although previous clinical trials demonstrated that ticagrelor could reduce cardiovascular events and mortality versus clopidogrel in patients with acute coronary syndrome (ACS), the real-world evidence of its clinical impacts on East Asian Diabetic population has rarely been investigated.

Between November 2013 and June 2015, 1534 patients were recruited into the Acute Coronary Syndrome-Diabetes Mellitus Registry of the Taiwan Society of Cardiology (TSOC ACS-DM registry). After propensity score matching, a total of 730 patients undergoing successful revascularization and discharged on ticagrelor (N=365) or clopidogrel (N=365) were analyzed. The primary and secondary endpoints were all-cause mortality and re-hospitalization, respectively. The all-cause death associated with ticagrelor vs clopidogrel was 3.6% vs 7.4% (adjusted hazard ratio (HR) 0.34 [0.15–0.80]; \( P = .0138 \)) at 24 months. The re-hospitalization rate at 24 months was 38.9% vs 39.2% (\( P = .3258 \)).

For diabetic patients with ACS, ticagrelor provided better survival benefit than clopidogrel without an increase of re-hospitalization in 24 months after successful percutaneous coronary intervention. This study in real-world circumstance provided valuable complementary data to externally validate platelet inhibition and patient outcomes (PLATO) finding especially in Asian diabetic population.

Abbreviations: ACS = acute coronary syndrome, AMI = acute myocardial infarction, CI = confidence interval, DAPT = dual antiplatelet therapy, DM = diabetes mellitus, HR = hazard ratio, KAMIR-NIH = Korea Acute Myocardial Infarction Registry-National Institute of Health, NNT = number-needed-to-treat, OR = odds ratio, PCI = percutaneous coronary intervention, PLATO = platelet inhibition and patient outcomes, PSM = propensity score matching, STEMI = ST elevation myocardial infarction, THEMIS = Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study, TIMI = thrombolysis in myocardial infarction, TSOC ACS-DM registry = Acute Coronary Syndrome-Diabetes Mellitus Registry of the Taiwan Society of Cardiology.

Keywords: acute coronary syndrome, clopidogrel, diabetes, ticagrelor

Editor: Salvatore De Rosa.

Funding supports are from Taiwan Society of Cardiology and Taipei Medical University Wanfang Hospital 105swf06.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

* Division of Cardiovascular Medicine, Department of Internal Medicine, Taipei Municipal Wan-Fang Hospital, Taipei, \# Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, † Taipei Heart Institute, ‡ Ph.D Program of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, § Ph.D Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, \* Master Program in Applied Molecular Epidemiology, College of Public Health, Taipei Medical University, ¶ Division of Cardiology, Department of Internal Medicine and Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, || Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taiwan.

† Correspondence: Jong-Shiuan Yeh, Division of Cardiology, Department of Internal Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan (e-mail: yvesyeh@gmail.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Wang CA, Hsieh YC, Huang CY, Liu JC, Hsieh MH, Lin YK, Yeh JS. Comparison between Ticagrelor versus Clopidogrel in Long Term Outcomes of Taiwanese Diabetic Subjects with Acute Coronary Syndrome Undergoing Successful Revascularization; from TSOC ACS-DM Registry. Medicine 2020;99(19):e19969.

Received: 5 November 2019 / Received in final form: 21 February 2020 / Accepted: 18 March 2020

http://dx.doi.org/10.1097/MD.0000000000019969
1. Introduction

The Asia-Pacific region is populated by more than 4.2 billion inhabitants, equivalent to 60% of the world’s population. Acute coronary syndrome (ACS) is now a major cause of death and disability in this region with in-hospital mortality typically exceeding 5%.[11] Diabetes mellitus (DM) is one of the most important risk factors for coronary artery disease and the prevalence of which is increasing globally, especially in Asian countries. Moreover, in diabetic patients, platelet reactivity is increased providing a proinflammatory state, which is even much more pronounced during ACS.[2] Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist, especially in those undergoing percutaneous coronary intervention (PCI) has become one of the established standard of treatment for ACS.[1,4] Clopidogrel has been used extensively worldwide as the P2Y12 receptor antagonist with aspirin for more than a decade. A drawback of clopidogrel is that as a pro-drug, it needs liver metabolism to be activated. Moreover, this pathway is susceptible to genetic polymorphism, which may lead to unexpected variations in drug activity.[5,6] In particular, studies have consistently shown that some population, like Asian and DM patients have higher prevalence of impaired clopidogrel-induced antiplatelet effects compared with other population.[2,7,8]

In the global Phase III PLATO trial, ticagrelor, a novel and more potent P2Y12 receptor antagonist, has been demonstrated to reduce the composite of myocardial infarction, stroke and death from cardiovascular cause, without increasing overall major bleeding than clopidogrel in patients with ACS.[9] However, the efficacy and safety in the East Asian population have not been well established.[10] The studies showed that Asian patients are more susceptible to antithrombotics or fibrinolysis[11,12] and to be associated with a higher bleeding risk during management of ischemic heart diseases and antithrombotic therapy.[13] Although the subgroup analysis from PLATO study revealed consistent profile of effects and safety in Asian and in diabetic patients receiving ticagrelor and clopidogrel,[14] another phase III PHILo trial that was designed to mirror PLATO trial but only included East Asian population showed the event rates of primary safety and efficacy endpoints were higher, albeit not significantly, in patient treated with ticagrelor compared with clopidogrel.[15] As such, we undertook the present observational study to evaluate outcomes in ACS DM patient, a very high risk population, after receiving percutaneous coronary intervention and treated with ticagrelor or clopidogrel, who were enrolled into the Acute Coronary Syndrome-Diabetes Mellitus Registry of the Taiwan Society of Cardiology (TSOC ACS-DM Registry).

2. Methods

2.1. Study patients

All patients were participants in the TSOC ACS-DM Registry. This was a prospective, nationwide, multicenter, non-interventional, observational clinical registry-based study, and the recruitment procedure has been detailed elsewhere.[16] In brief, the inclusion criteria were patients

1) who had admitted to the hospital with ACS within the previous 30 days;
2) with a history of type 2 DM or newly diagnosed DM defined according to the world health organization criteria;
3) aged ≥20 years; and
4) agreed to provide informed consent.

The exclusion criteria were patients

1) who had crossover from clopidogrel to ticagrelor or from ticagrelor to clopidogrel during study;
2) who did not take clopidogrel and ticagrelor;
3) who did not receive primary PCI;
4) with serum creatinine over 5 mg/dL; and
5) with ACS accompanied by or precipitated by a significant comorbidity such as motor vehicle accidents, trauma, severe gastrointestinal bleeding, peri-operative or peri-procedural myocardial infarction, or those participating in an investigational drug study.

Therefore, a total of 1534 patients with existing or newly diagnosed DM and aged >20 years with ACS within the previous 30 days were recruited from 2013 through 2015.

According to the regulations of the Taiwan National Health Insurance system, the use of dual antiplatelet therapy can be reimbursed during a period of no longer than 9 months after the index ACS event. Ticagrelor became available in Taiwan in the latter half of 2013. The inclusion period for the present study was selected so as to span the period when clopidogrel dominated until the time when ticagrelor was well established in clinical practice in Taiwan and was chosen a priori to achieve adequate statistical power.

In this study, the clopidogrel group (n = 917) and the ticagrelor group (n = 450) were categorized according to patients who received dual antiplatelet therapy with clopidogrel or ticagrelor at the discharge of their in-hospital procedures. The dosage of clopidogrel and ticagrelor was according to the current Taiwanese guideline.[17] Further, patients were eligible for this study if they received primary PCI. In order to reduce sample selection bias, propensity score matching (PSM), which is commonly used in observational studies,[18–20] was performed to result in similar baseline characteristics between the clopidogrel and ticagrelor groups. In this study, the propensity score was measured on the variables shown in Table 1. The detailed process of patient selection is presented in Figure 1. Baseline demographic information, clinical symptoms, biochemistry data, and in-hospital procedures and outcomes, including 6-month, 1-year, and 2-year mortality, were collected as described previously.[16] The primary endpoint was death from any causes. Re-hospitalization was the secondary endpoint in this study. All data were submitted electronically by study nurses to a central laboratory for verification.

Continuous variables were presented as means and standard deviations when they were normally distributed and were compared using the Student t test; otherwise they were shown as medians and interquartile ranges and were analyzed using the Mann–Whitney U test. Categorical data were provided as numbers and percentages were examined using the chi-square test. Kaplan–Meier estimates and log-rank tests were performed to evaluate survival over 1- and 2-year periods between the clopidogrel and ticagrelor groups. Cox proportional hazards models were applied to compare the mortality between the clopidogrel and ticagrelor groups. The potential risk factors were further adjusted in the multivariate Cox proportional hazards models. The stratified estimates of 1- and 2-year mortality risk were further performed. A low thrombolysis in myocardial infarction (TIMI) score was defined as <3 for patients with ST elevation myocardial infarction (STEMI) and <5 for patients with non-STEMI/unstable angina; a high TIMI score was defined as ≥3 for STEMI patients and ≥5 for non-STEMI/unstable angina.
patients. All statistical analyses were performed using statistical analysis system version 9.4 (SAS Institute Inc., Cary, NC), and a $P$-value < .05 was considered statistically significant.

### 3. Results

Table 1 shows the baseline characteristics of clopidogrel and ticagrelor groups after PSM. These 2 groups exhibited non-significant differences for all covariates. The mean age was 63.0 ± 11.9 and 62.7 ± 11.6 for patients who took clopidogrel and ticagrelor, respectively. Around 75% subjects were male in both groups.

The culprit artery territories, left ventricle ejection fraction, number of diseased vessel, use of an intra-aortic balloon pump, stent type, PCI, implantable cardioverter defibrillator, and medication use among the clopidogrel and ticagrelor groups were comparable (Table 2). Patients in the ticagrelor group reported taking coronary artery bypass grafting surgery significantly less frequently than did those in the clopidogrel group. In addition, the mean durations of treatment in the clopidogrel and ticagrelor groups were 7.8 ± 3.6 months vs 6.7 ± 3.2 months ($P < .0001$). Table 3 shows the in-hospital bleeding status, patients in the ticagrelor group presented a higher rate of bleeding according to the TIMI criteria [21] during the ACS admission, but the 2 groups did not differ significantly with respect to the rates of major or minor bleeding type.

Figure 2 compares the all-cause mortality rate and re-hospitalization rate at 2 years between patients in the clopidogrel and ticagrelor groups. Compared with the patients who received clopidogrel, those who received ticagrelor had lower incidences of all-cause death at 2 years (log-rank test $P = .0404$), with adjusted hazard ratios (HRs) of 0.34 (95% confidence interval [CI], 0.15–0.80; $P = .0138$) (Table 4). However, the results did not reach statistical significance for re-hospitalization at 2 years. In stratified analyses based on gender, age, TIMI score, and ACS diagnosis status, a prominently lower 2-year mortality risk was observed among females and patients aged ≥ 65 years in the ticagrelor group compared with patients in the clopidogrel group (Fig. 3).
Figure 1. Participant selection flow chart.

### Table 2
Treatments and procedures of the patients who take clopidogrel and ticagrelor, respectively.

| Characteristics                        | Clopidogrel Group (N = 365) | Ticagrelor Group (N = 365) | P-value |
|---------------------------------------|----------------------------|-----------------------------|---------|
| Culprit artery territory, n (%)       |                            |                             |         |
| LM                                    | 8 (2.2)                    | 4 (1.1)                     | 0.4030  |
| LAD                                   | 162 (44.4)                 | 155 (42.5)                  |         |
| LCx                                   | 61 (16.7)                  | 72 (19.7)                   |         |
| RCA                                   | 106 (29.0)                 | 114 (31.2)                  |         |
| Unknown                               | 28 (7.7)                   | 20 (5.5)                    |         |
| Ejection fraction                     |                            |                             |         |
| Normal                                | 152 (51.4)                 | 167 (59.2)                  | 0.1451  |
| Mild (40–50%)                         | 86 (23.1)                  | 69 (24.5)                   |         |
| Moderate (50–75%)                     | 34 (11.5)                  | 31 (11.0)                   |         |
| Severe (>75%)                         | 23 (7.8)                   | 12 (4.3)                    |         |
| Not done                              | 1 (0.3)                    | 3 (1.1)                     |         |
| Disease vessel                        |                            |                             |         |
| 0                                     | 1 (0.3)                    | 4 (1.1)                     | 0.0019  |
| 1                                     | 109 (32.9)                 | 156 (45.5)                  |         |
| 2                                     | 98 (27.0)                  | 87 (24.4)                   |         |
| 3                                     | 125 (37.8)                 | 96 (28.0)                   |         |
| Intra aortic balloon pump, n (%)      |                            |                             |         |
| 72 (19.7)                             | 62 (17.0)                  | 0.3390                      |
| Stent type, n (%)                     |                            |                             |         |
| BMS                                   | 131 (36.0)                 | 119 (32.6)                  | 0.0035  |
| DES                                   | 153 (42.0)                 | 185 (50.7)                  |         |
| Both                                  | 12 (3.3)                   | 7 (1.9)                     |         |
| Others (biodegradable)                | 1 (0.3)                    | 9 (2.5)                     |         |
| None/unknown                          | 67 (18.4)                  | 45 (12.3)                   |         |
| PCI lesions successfully treated, n (%)| 295 (79.7)                 | 323 (97.9)                  | 0.5009  |
| Coronary artery bypass grafting status, n (%)| 10 (2.7)                  | 2 (0.6)                     | 0.0199  |
| ICD, n (%)                            | 2 (0.6)                    | 1 (0.3)                     | 1.0000  |
| Medications, n (%)                    |                            |                             |         |
| Aspirin                               | 337 (92.3)                 | 345 (94.5)                  | 0.2322  |
| GP IIb/IIIa inhibitors                | 24 (6.6)                   | 26 (7.1)                    | 0.7695  |
| ACE inhibitor                         | 150 (41.1)                 | 154 (42.2)                  | 0.7629  |
| Angiotensin II receptor blocker       | 113 (31.0)                 | 119 (32.6)                  | 0.6334  |
| Oral beta blocker                     | 252 (69.0)                 | 264 (72.3)                  | 0.3292  |
| Statin                                | 290 (79.5)                 | 300 (82.2)                  | 0.3472  |
| Ca++ antagonist                       | 78 (21.4)                  | 63 (17.3)                   | 0.1596  |
| Medication duration, mo, mean (SD)    | 7.8 (3.0)                  | 6.7 (3.2)                   | <0.0001 |

**AC**e=angiotensin-converting-enzyme, **BMS**=bare metal stent, **DES**=drug eluting stent, **ICD**=implantable cardioverter defibrillators, **LAD**=left anterior descending coronary artery, **LCx**=left circumflex coronary artery, **LM**=left main coronary artery, **PCI**=percutaneous coronary intervention, **RCA**=right coronary artery, **SD**=standard deviation.
4. Discussion

This study from sub-analysis of the nationwide, multicenter registry was conducted to compare the real-world outcome of East Asian diabetes population, mostly Taiwanese patients with ACS treated with ticagrelor versus clopidogrel after PCI. The main finding is that patients treated on ticagrelor post PCI had lower all-cause mortality without increasing any hospitalization. And the survival benefit persisted up to 2 years after. Therefore, ticagrelor might be an appropriate antiplatelet agent in addition to aspirin in East Asian diabetes population with ACS after PCI.

DAPT is a cornerstone of therapy for patients with acute coronary syndrome.[3] Clopidogrel has been used extensively worldwide for more than a decade. However, a drawback of clopidogrel is that it is a pro-drug, which means that it needs to be activated by liver metabolism.[22] In diabetes patients with ACS, the drug metabolism may be hampered by these specific circulatory circumstances and delay the antiplatelet effect especially in those patients undertaking PCI.[2,23] Furthermore, this pathway is susceptible to genetic polymorphism, which may lead to unexpected variations in drug activity. Besides, Asian patients have been reported as poor clopidogrel metabolizers due to the prevalence of cytochrome P450 2C19 (CYP2C19) loss-of-function alleles.[24–26]

Ticagrelor is an oral, direct-acting antiplatelet agent that binds reversibly to the P2Y12 receptor and has a more rapid onset and robust antiplatelet effect compared with clopidogrel.[27] Ticagrelor is recommended by current ACS guidelines based on the PLATO trial.[14] Although the use of ticagrelor for ACS has been increasing across Asia, there is a paucity of evidence regarding the efficacy and safety of ticagrelor in this population.[23] The PHILO study was a multicenter, randomized, double-blind study which was designed as PLATO and conducted in Japan and East Asian countries (Japan, 90%; South Korea, 6%; Taiwan, 4%).[15] But ticagrelor failed to demonstrate the benefit in PHILO study. The incidence of the composite primary end point (cardiovascular death, myocardial infarction, and stroke) was 10.2% (34 events) per year with ticagrelor and 8.1% (24 events) per year with clopidogrel (odds ratio (OR) 1.47, 95% CI 0.88–2.44). However, a retrospective nationwide cohort study compared clinical outcome of ticagrelor and clopidogrel in acute myocardial infarction (AMI) patients by using Taiwan National Health Insurance Database found the primary efficacy endpoint rate, including death from any cause, AMI, or stroke was 22% lower in the ticagrelor group than in the clopidogrel group (10.6% and 16.2%, respectively; adjusted hazard ratio (HR), 0.779; 95% CI: 0.684–0.887).[29] Another nationwide retrospective cohort study from Korean health insurance review and assessment data also revealed that ticagrelor had a significant effect on reduction of all-cause death without increasing major bleeding than clopidogrel in AMI patients after PCI.[30] To clarify the survival benefit of ticagrelor in East Asian ACS population after successful PCI in the real-world circumstance, we designed current study from the nationwide TSOC ACS DM registry. We found a lower all-cause mortality rate in the ticagrelor group than in the clopidogrel group (3.3% versus 4.9%) at 1 year follow up. A study from Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH) included 2754 AMI patients after successful PCI and evaluated the short-term outcome of ticagrelor and clopidogrel. No difference in the composite of cardiac death, myocardial infarction, stroke, or target vessel revascularization at

| Table 3 | The in-hospital bleeding status of the patients who take clopidogrel and ticagrelor, respectively. |
|---------|--------------------------------------------------------------------------------------------------|
|         | Clopidogrel (N = 365)                                                                 | Ticagrelor (N = 365)                                                                 | P-value |
| In hospital TIMI bleed | No 350 (95.9) | 363 (99.5) | .0014 |
|         | Yes 15 (4.1) | 2 (0.6) | 1.0000 |
| TIMI major/minor bleed type | Major 12 (80.0) | 2 (100.0) | 0 (0) |
|         | Minor 3 (20.0) | 0 (0) | 0 (0) |
| Blood transfusion | No 353 (96.7) | 363 (99.5) | .0070 |
|         | Yes 12 (3.3) | 2 (0.6) | 0.0000 |

Figure 2. Cumulative Kaplan-Meier estimates of the time to death (A) and hospitalization (B) at 2 yr, respectively, between the patients who take clopidogrel and ticagrelor.
6 months was observed between 2 groups (4.2% vs 4.9%, \( P = .499 \)).[31] Both KAMIR-NIH and TSOC ACS-DM registry mainly included relatively stable patients with ACS after successful revascularization. One of the differences between our study and KAMIR-NIH is that our study population consisted entirely of diabetic ACS patients, which is a very high-risk diseased population requiring aggressive intervention. The beneficial effect of any intervention in the high-risk population could be subsequently translated into a smaller number-needed-to-treat (NNT) as compared to that in the general population. For example, by using ticagrelor vs clopidogrel, the NNT for 1-year and 2-year all-cause mortality in our study was 63 and 27, respectively.

Besides, in diabetic and ACS patients, platelet reactivity is increased given a proinflammatory state and the clopidogrel-mediated platelet inhibitory effects may be deteriorated in DM patients.[2,32] Compared with clopidogrel and prasugrel, ticagrelor achieved not only faster, enhanced platelet inhibition and reduced high on-treatment platelet reactivity rates, but also significantly decreased inflammatory cytokines and increased

| Table 4 | Endpoints of the patients who take clopidogrel and ticagrelor, respectively. |
|---------|---------------------------------------------------------------|
|         | Clopidogrel group (N = 365) | Ticagrelor group (N = 365) | HR   | 95% CI | P-value | HR   | 95% CI | P-value |
| All-cause mortality (N, %) | | | | | | | | |
| 6 mo    | 12 (3.3) | 7 (1.9) | 0.63 | 0.25-1.60 | .3301 | 0.61 | 0.22-1.71 | .3476 |
| 1 yr    | 18 (4.9) | 12 (3.3) | 0.67 | 0.32-1.39 | .2799 | 0.43 | 0.18-1.05 | .0652 |
| 2 yr    | 27 (7.4) | 13 (3.6) | 0.51 | 0.26-0.98 | .0444 | 0.34 | 0.15-0.80 | .0138 |
| Hospitalized (N, %) | | | | | | | | |
| 6 mo    | 74 (20.3) | 88 (24.1) | 1.30 | 0.95-1.77 | .1030 | 1.62 | 1.14-2.30 | .0077 |
| 1 yr    | 119 (32.6) | 131 (35.9) | 1.17 | 0.91-1.49 | .2311 | 1.24 | 0.94-1.64 | .1296 |
| 2 yr    | 143 (39.2) | 142 (38.9) | 1.05 | 0.83-1.33 | .6786 | 1.14 | 0.88-1.48 | .3258 |

* Adjustment for ECG findings at study entry, Killip classification, Peak CK, stent type, coronary artery bypass grafting status, and disease vessels.
circulating endothelial progenitor cells, contributing to improved arterial endothelial function in diabetic acute coronary syndrome patients.\textsuperscript{[23,33]} Another difference is that our study provided long term outcome up to 2 years. We noted lower mortality rate trend of ticagrelor group at 6 months and 12 months (1.9% versus 3.3% and 3.3% versus 4.9%). And we also noted the difference in survival benefit is consistent and significant at the analysis of 24 months (3.6% versus 7.4%; adjusted HRs =0.46; 95% CI: 0.23–0.92; \(P=0.0271\)), although the treatment period of ticagrelor group is 6.7 ± 3.2 months only, which is less than clopidogrel group. The possible explanation is that the pleiotropic effects of ticagrelor on longer-term clinical course beyond its potent antiplatelet effects such as restoration of endothelial function or tissue perfusion could contribute to additional clinical benefits in the study population.\textsuperscript{[27]} Our study showed a lower 2-year mortality risk in females and patients aged ≥65 years in the ticagrelor group. Yaseen et al found diabetes mellitus, hypertension, obesity, and male sex were the major independent predictors for clopidogrel non-responder. They also found younger age was a protective factor.\textsuperscript{[15]} These findings can explain why females and elderly patients had better outcome in the ticagrelor group.

In our study, the incidence of in-hospital bleeding including TIMI major or minor bleeding are relatively low in both ticagrelor and clopidogrel group, which may be attributable to missing information or incomplete patient records. Because minor bleeding events were possibly not fully reported and incomplete in the registry, the total bleeding events might be underestimated in the present study. However, ticagrelor had consistent similar re-hospitalization rate with clopidogrel during follow up period.

Recently, topline results of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) study has been early released.\textsuperscript{[33]} By enrolling 19,271 patients with diabetes and established coronary artery disease but no history of myocardial infarction or stroke, ticagrelor has been shown to reduce major adverse cardiovascular events as compared to placebo. To be noted, there are some key differences between our study and THEMIS including study population (DM with ACS vs DM) and intervention strategy. As such, the indispensable role of our study as a real-world evidence to inform clinical decisions with complementary data to randomized controlled trials still exists.

There are some key limitations in the present study. First, our study was a non-randomized study, but based on a prospective, observational registry, therefore, selection bias was hardly avoidable, which opens the possibility of residual confounding which is a known potential source of error in registry studies. Even though it was partially compensated by multivariate Cox proportional hazard models. Second, the absolute risk of bleeding is lower in the registry than the risk seen in clinical trials. It is conceivable that this relates to underreporting of bleeding events in the registry. Third, we could not accurately evaluate other adverse effects of P2Y12 inhibitors including dyspnea, heart block, or bruising. Fourth, the actual treatment duration and attrition are unavailable in the present analysis which is based on intention to treat. However, as more patients in the ticagrelor arm discontinued their study drug than in the clopidogrel arm, we still found the survival benefit of ticagrelor over clopidogrel up to 2 years follow up. Fifth, there was no data for clopidogrel non-response or semi-response in TSOC ACS-DM registry. Although we excluded all patients needed to shift clopidogrel to ticagrelor, the clopidogrel non-/semi-response might still interfere our study.

In conclusion, ticagrelor versus clopidogrel treatment at discharge in diabetic patients with ACS after PCI was associated with a lower adjusted risk of death without an increase in the rate of overall re-hospitalization during 24-months follow-up. This study in real-world circumstance provided important complementary data to externally validate PLATO finding especially in the high-risk Asian diabetic population.

Acknowledgments

On behalf of the TSOC ACS DM registry study group: Wei-Hsian Yin, Chih-Cheng Wu, Shih-Hung Chan, Yen-Wen Wu, Kuo-Yung Wang, Juey-Jen Hwang, Kuan-Cheng Chang, Wen-Chol Voon, I-Chang Hsieh, Kou-Gi Shyu, Jun Ted Chong, Wei-Shiang Lin, Chih-Neng Hsu, Kuo-Chang Ueng, Chih-Ping Hsia, Jong Shiuan Yeh, Ju-Chi Liu Guang-Yuan Mar, Jihi-Yuan Shih, Jen-Yuan Kuo, Hsuan-Ming Tsao, Wei-Kung Tseng, Cheng-Hsu YANG, Chao-Chien Chang, Jeng-Feng Lin, Chern-En Chiang, Meng-Huan Lei.

Author contributions

Conceptualization: Cheng-An Wang, Jong-Shiuan Yeh.
Formal analysis: Yi-Chen Hsieh.
Investigation: Yi-Chen Hsieh.
Methodology: Chun-Yao Huang.
Supervision: Ju-Chi Liu, Ming-Hsiung Hsieh, Yung-Kuo Lin.
Writing – original draft: Cheng-An Wang.
Writing – review & editing: Cheng-An Wang, Jong-Shiuan Yeh.

References

[1] Chan MY, Du X, Eccleston D, et al. Acute coronary syndrome in the Asia-Pacific region. Int J Cardiol 2016;202:861–9.
[2] Angiolillo DJ, Jakubowski JA, Ferreiro JL, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 2014;64:1005–14.
[3] Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745–54.
[4] Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:2354–94.
[5] Bhatt DL, Paré G, Eikelboom JW, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 2012;33:2143–50.
[6] Hasan MS, Basri HB, Hrn LP, et al. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci 2013;123:143–34.
[7] Zafar MU, Baber U, Smith DA, et al. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost 2017;117:1981–8.
[8] Tan DS, Yeo AH, Ho HK, et al. Asian study of clopidogrel (ASCLOP) responsiveness: the contributions of genetic and non-genetic factors. Int J Cardiol 2014;171:e21–3.
[9] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57.
[10] Misumida N, Aos S, Kim SM, et al. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis. Cardiovasc Revasc Med 2018;19:689–94.
[11] Dang M-TN, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005;39:1008–12.

[12] Ma C. Current antithrombotic treatment in East Asia: some perspectives on anticoagulation and antiplatelet therapy. Thromb Haemost 2012; 107:1014–8.

[13] Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014;11:597–606.

[14] Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J 2015;169:899–905, e891.

[15] Goto S, Huang CH, Park SJ, et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome – randomized, double-blind, phase III PHILO study. Circ J 2015;79:2452–60.

[16] Chen KC, Yin WH, Wu CC, et al. In-hospital implementation of evidence-based medications is associated with improved survival in diabetic patients with acute coronary syndrome – data from TSOC ACS-DM Registry. Acta Cardiol Sin 2018;34:211–23.

[17] Li YH, Wang YC, Wang YC, et al. 2018 Guidelines of the Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. J Formos Med Assoc 2018;117:766–90.

[18] Faries D, Leon A, Haro J, et al. Analysis of Observational Health Care Data Using SAS. 2010:SAS Publishing.

[19] Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33–8. DOI 10.1080/00031305.1985.10479383.

[20] Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55.

[21] Mehran R, Rao SV, Bhart D, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736–47.

[22] Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–73.

[23] Sweeney JM, Angiolillo DJ, Franchi F, et al. Impact of diabetes mellitus on the pharmacodynamic effects of ticagrelor versus clopidogrel in troponin-negative acute coronary syndrome patients undergoing ad hoc percutaneous coronary intervention. J Am Heart Assoc 2017;6: DOI 10.1161/JAHA.117.005650.

[24] Lin R, Zhang L, Zhang P, et al. Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China. J Clin Pharm Ther 2013;40:308–14.

[25] Xi Z, Fang F, Wang J, et al. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis. Platelets 2019;30:229–40.

[26] Amin AM, Sheau Chin L, Mohamed Noor DA, et al. The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients. Thromb Res 2017;158:22–4.

[27] Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2014;34:1077–90.

[28] Wu B, Lin H, Tobe RG, et al. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. J Comp Eff Res 2018;7:281–91.

[29] Lee CH, Cheng CL, Kao Yang YH, et al. Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. clopidogrel in Taiwan. Circ J 2018;82:747–56.

[30] Kim C, Shin D-H, Hong S-J, et al. One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: from Korean Health Insurance Review and Assessment Data. J Cardiol 2019;73:191–7.

[31] Park KH, Jeong MH, Ahn Y, et al. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. Int J Cardiol 2016;215:193–200.

[32] Hamilos M, Petousis S, Xanthopoulou I, et al. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy. Coron Artery Dis 2018;29:53–9.

[33] Jeong HS, Hong SJ, Cho SA, et al. Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non-ST-segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial. JACC Cardiovasc Interv 2017;10:1646–58.

[34] Yasen IF, Farhan HA, Abbas HM. Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: frequency and predictors. Eur J Hosp Pharm 2019;26:113–6.

[35] Bhart D, Fox K, Harrington RA, et al. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol 2019;42:498–505.